Received Jul 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
couldn't get the third dose; Interval is more than recommended between dose 1 and 2; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in an adult male patient who received HBV (Engerix B) for prophylaxis. Co-suspect products included HBV (Engerix B) for prophylaxis. Previously administered products included Engerix B (Received 1st dose of Engerix B vaccine on 01-SEP-2024). On 12-OCT-2024, the patient received the 2nd dose of Engerix B. The patient did not receive the 3rd dose of Engerix B. On 12-OCT-2024, an unknown time after receiving Engerix B, the patient experienced drug dose administration interval too long (Verbatim: Interval is more than recommended between dose 1 and 2). The patient had incomplete course of vaccination (Verbatim: couldn't get the third dose). The outcome of the drug dose administration interval too long and incomplete course of vaccination were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 18-JUL-2025 Pharmacist wanted to know how to proceed with a patient that received the first two doses of Engerix-B back on 01-Sept-2024 and 12-Oct-2024, respectively, which led to drug dose administration interval too long. The patient couldn't get the third dose which led to incomplete course of vaccination and now wanted to receive it. These two doses were given in another facility.